Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Prelude Therapeutics
ABM Therapeutics Corporation
Quadriga Biosciences, Inc.
Celgene
AbbVie
Celgene
Tocagen Inc.
AbbVie
National Cancer Institute (NCI)
Case Comprehensive Cancer Center
Pharmacyclics LLC.